Martin Everett, Ph.D., appointed Chief Scientific Officer, will oversee the company’s product pipeline structuration and subsequent research and development activities.
Lyon (France), Monday February 13th, 2023 AUROBAC THERAPEUTICS SAS, a biopharmaceutical company developing the next generation of products to fight AntiMicrobial Resistance (AMR), today announced the appointment of Martin Everett as Chief Scientific Officer.
With over 30 years’ experience in academia, pharmaceutical R&D (GSK) and biotechnology companies (MerLion, ANTABIO), Martin Everett is an expert in antibacterial discovery and development. He has authored over 30 publications in peer-reviewed journals and has a strong experience in the antimicrobial resistance field. At GSK, he managed a high-throughput screening group and led several lead discovery projects. At MerLion, he was Head of Research leading a multi-disciplinary team discovering novel natural product derived compounds. At ANTABIO, Martin was Chief Scientific Officer and led all R&D activities towards the development of novel approaches to combat AMR. Martin will play a key role in building AUROBAC’s product pipeline in the AMR field and will lead the company’s R&D activities.
Commenting on the appointment, AUROBAC THERAPEUTICS CEO Florence Séjourné: “I am delighted that Martin is joining us. His incredibly strong knowledge and experience will be instrumental in helping us achieve our ambitious goals and making a profound impact in the field of antimicrobial resistance.”
Martin Everett, Ph.D., newly appointed CSO, commented: “I am very excited to join AUROBAC and contribute to the development of new solutions in the field of antimicrobial resistance. I believe that AUROBAC will make a significant impact in this area by shifting the strategy related to antibiotic treatment regimens towards a much-needed precision approach, using new highly effective and targeted modalities, combined with rapid and actionable diagnostics. I look forward to working with the outstanding team to bring the next generation of antimicrobials to patients in need.”
Full PR available here.